ATE121629T1 - Stabile interleukine enthaltende impfstoffzusammensetzungen. - Google Patents

Stabile interleukine enthaltende impfstoffzusammensetzungen.

Info

Publication number
ATE121629T1
ATE121629T1 AT90911344T AT90911344T ATE121629T1 AT E121629 T1 ATE121629 T1 AT E121629T1 AT 90911344 T AT90911344 T AT 90911344T AT 90911344 T AT90911344 T AT 90911344T AT E121629 T1 ATE121629 T1 AT E121629T1
Authority
AT
Austria
Prior art keywords
vaccine compositions
compositions containing
interleukin
mineral
interleukins
Prior art date
Application number
AT90911344T
Other languages
English (en)
Inventor
Subramonia Pillai
Garvin Bixler
Original Assignee
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc filed Critical Praxis Biolog Inc
Application granted granted Critical
Publication of ATE121629T1 publication Critical patent/ATE121629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90911344T 1989-07-14 1990-07-16 Stabile interleukine enthaltende impfstoffzusammensetzungen. ATE121629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14

Publications (1)

Publication Number Publication Date
ATE121629T1 true ATE121629T1 (de) 1995-05-15

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911344T ATE121629T1 (de) 1989-07-14 1990-07-16 Stabile interleukine enthaltende impfstoffzusammensetzungen.

Country Status (12)

Country Link
EP (1) EP0482076B1 (de)
JP (2) JP3485184B2 (de)
KR (1) KR0177179B1 (de)
AT (1) ATE121629T1 (de)
AU (1) AU648509B2 (de)
CA (1) CA2063587C (de)
DE (1) DE69018990T2 (de)
DK (1) DK0482076T3 (de)
ES (1) ES2075900T3 (de)
FI (1) FI104233B1 (de)
NO (1) NO301577B1 (de)
WO (1) WO1991001143A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
ZA919907B (en) * 1990-12-19 1992-08-26 Schering Corp Use of il-4 to enhance immune response to immunogens in vaccines
JPH07500813A (ja) * 1991-05-13 1995-01-26 リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア リポソーム多糖体ワクチン
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
EP0655927B1 (de) * 1992-08-10 1997-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Interleukin-4 stimulierter t-lymphozyten-zelltod
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
DE69735856T2 (de) * 1996-05-31 2006-11-16 National University Of Ireland Maynooth, Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU1813701A (en) 1999-12-03 2001-06-12 Celltech Chiroscience Limited Interleukin-1 muteins useful as vaccine adjuvants
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2007039584A1 (en) * 2005-09-30 2007-04-12 Lipoxen Technologies Limited Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
CA2655080A1 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
DK2925297T3 (en) * 2012-11-02 2017-10-02 Cytuvax COMPOSITION COMPREHENSIVE CYTOCHINE MACROAGGERATES
JP7478144B2 (ja) * 2018-10-12 2024-05-02 セラム インスティチュート オブ インディア プライベイト リミテッド 低減用量の不活化ポリオウイルスを含む混合ワクチン組成物およびそれを調製するための方法
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
EP4232070A1 (de) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Verfahren zur induktion von stammzellenmobilisierung
EP4236989A1 (de) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Verwendung von interleukin-7 zur behandlung des coronavirus
EP4240408A1 (de) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Verfahren zur behandlung eines tumors mit einer kombination aus einem il-7-protein und einem nukleotidimpfstoff
AU2022283271A1 (en) 2021-05-24 2023-12-07 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250099542A1 (en) 2021-12-30 2025-03-27 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
FI920132A0 (fi) 1992-01-13
EP0482076B1 (de) 1995-04-26
WO1991001143A1 (en) 1991-02-07
NO920161D0 (no) 1992-01-13
DK0482076T3 (da) 1995-07-17
FI104233B (fi) 1999-12-15
JP3485184B2 (ja) 2004-01-13
CA2063587C (en) 2005-08-30
KR0177179B1 (ko) 1999-03-20
DE69018990T2 (de) 1995-12-14
ES2075900T3 (es) 1995-10-16
AU6050090A (en) 1991-02-22
FI104233B1 (fi) 1999-12-15
EP0482076A1 (de) 1992-04-29
AU648509B2 (en) 1994-04-28
DE69018990D1 (de) 1995-06-01
JP2004002463A (ja) 2004-01-08
JPH04506663A (ja) 1992-11-19
KR920703103A (ko) 1992-12-17
NO920161L (no) 1992-03-05
CA2063587A1 (en) 1991-01-15
NO301577B1 (no) 1997-11-17

Similar Documents

Publication Publication Date Title
ATE121629T1 (de) Stabile interleukine enthaltende impfstoffzusammensetzungen.
FI945483L (fi) Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
GB8403921D0 (en) Preparation of lyophilized adsorbed polyvalent vaccines
GB2129089B (en) Combined spring and damper using elastomeric particles as fluid
MX9803290A (es) Composiciones de la vacuna influenza.
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
ATE275421T1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
NO892169D0 (no) Zn-modifisert silika og fremgangsmaate for dets fremstilling.
WO2001039803A3 (en) Interleukin-1 muteins useful as vaccine adjuvants
ES2111031T3 (es) Uso de preparaciones que contienen anticuerpos para la inmunosupresion.
ATE230615T1 (de) Regulierung der systemischen immunantworten mittels zytokinen und antigenen
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
AU2415284A (en) Polypeptidic fractions inducing propective antibodies against malaria parasites and immunogenic compositions containing them
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
JPS55106261A (en) Composition made of dispersed body of colloid silica and colloid titania
IT8211575U1 (it) Modulo ripiegabile ed incollabile per spedizione postal, con zone prive di preincollaggio
YU47377B (sh) Suspenzija zeolita koja sadrži sil ikonat
FI924215A7 (fi) IL-4:n käyttö infektioosien antigeenisten aineiden aiheuttaman immuuni reaktion lisäämiseksi
GB8915572D0 (en) Use of bluetongue virus proteins as vaccine components
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
DE3869127D1 (de) Sorbentmittel fuer chlorosilanverbindungen.
GR1000881B (el) Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee